Please login to the form below

Not currently logged in
Email:
Password:

ZS Pharma

This page shows the latest ZS Pharma news and features for those working in and with pharma, biotech and healthcare.

Real-world data finds patients feel better on Entresto, says Novartis

Real-world data finds patients feel better on Entresto, says Novartis

Lokelma (sodium zirconium cyclosilicate or ZS-9) and Vifor Pharma’s Veltassa (patiromer) which “will be a particularly valuable addition to the clinic if efficacy can be confirmed in clinical trials”.

Latest news

  • AZ gets US approval for Veltassa rival Lokelma AZ gets US approval for Veltassa rival Lokelma

    AstraZeneca has picked up FDA approval for its hyperkalaemia treatment Lokelma, allowing it to compete head-to-head with rival Vifor Pharma on both sides of the Atlantic. ... AZ acquired Lokelma via the $2.7bn acquisition of ZS Pharma three years ago

  • FDA turns down AZ's ZS-9 once again on manufacturing issues FDA turns down AZ's ZS-9 once again on manufacturing issues

    AZ and ZS Pharma are committed to working with the FDA to resolve the remaining matters under review as soon as possible," it said in a statement. ... When AZ bought ZS Pharma it described ZS-9 as a "best in class" potassium-binder with sales potential

  • AZ nears EU approval for hyperkalaemia drug Lokelma AZ nears EU approval for hyperkalaemia drug Lokelma

    The drug was originally developed by ZS Pharma, which described Lokelma as a “ potential best-in-class treatment” and tipped it as a potential blockbuster. ... Speaking at the time of ZS Pharma's acquisition, AstraZeneca's chief executive Pascal

  • AZ slims down again with sale of antibiotics to Pfizer AZ slims down again with sale of antibiotics to Pfizer

    In May the big pharma company was estimated to be sitting on around $40bn - giving it plenty of scope to for pipeline-bolstering deals. ... Meanwhile, recent pipeline-boosting acquisitions have included a $2.7bn purchase of ZS Pharma, a majority stake in

  • Actelion claims first approval for PAH therapy Uptravi Actelion claims first approval for PAH therapy Uptravi

    It was also in discussions about a merger with ZS Pharma, before the latter opted instead for a $2.7bn takeover by AstraZeneca (AZ).

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Deal Watch May 2016 Deal Watch May 2016

    The CRL refers to a manufacturing issue. ZS-9 was acquired when the company purchased ZS Pharma for $2.7bn. ... Reported in DW Issue 65 [November 2015] AstraZeneca had out bid Actelion who were also in the running to buy ZS Pharma at that time.

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    metabolism. Meanwhile, further evidence for an uptick in pharma industry interest in HF is witnessed by recent licensing/acquisition deals. ... of ZS Pharma and ZS-9, a drug being developed to treat elevated potassium levels in HF patients.

  • Deal Watch November 2015 Deal Watch November 2015

    Also doing the double and buying and selling AstraZeneca continued its busy deal profile with the acquisition of ZS Pharma and the divestment in the US of Entocort. ... ZS Pharma. AstraZeneca. Acquisition - company. Lead product ZS-9, potassium-binding

  • Pharma deals in September 2015 Pharma deals in September 2015

    Transformational deals. The two largest deals announced this month were Cinven's sale of Amdipharm Mercury (AMCo) to Concordia Healthcare and Actelion's move to acquire ZS Pharma, at $3.5bn ... 3, 500. ZS Pharma. Actelion. ZS-9 to treat hyperkalemia

  • Sales reps struggle to access doctors Sales reps struggle to access doctors

    Relationships reached by sales force size. Source: ZS Associates. Making proper use of that well-worn buzz word 'customer-centric' marketing will be key - along with careful channel choice – if pharma ... companies are to gain physician attention, but

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics